The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta®) has been accepted for restricted use as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta-agonist. The restriction limits use to patients with severe COPD (forced expiratory volume in one second [FEV1] < 50% predicted normal).
Lacosamide (Vimpat®) has been accepted for restricted use as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy. The restriction limits use to patients with refractory epilepsy and should be initiated by physicians who have appropriate experience in the treatment of epilepsy.
Levonorgestrel (Kyleena®) has been accepted for use as a contraceptive for up to 5 years.
Sevelamer carbonate (Renvela®) has been accepted for restricted use to control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m2) with chronic kidney disease. The restriction limits use to second-line management of hyperphosphataemia in patients receiving haemodialysis and treatment would normally be initiated by a specialist.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Drug Safety Update - February 2018||CKS Updates - January 2018 »|